Gabapentinoid abuse in order to potentiate the effect of methadone: A survey among substance misusers

European Addiction Research

Volumn 20, Issue 3, 2014, Pages 115-118

  Baird, Colin R W ^a,b   Fox, Pauline ^b   Colvin, Lesley A ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; CANNABIS; DIAMORPHINE; GABAPENTIN; GABAPENTINOID; METHADONE; PREGABALIN; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID; AMINE; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE;

ARTICLE; CHRONIC PAIN; DRUG ABUSE; DRUG POTENTIATION; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; SUBSTANCE ABUSE; UNITED KINGDOM; ADDICTION; ANALOGS AND DERIVATIVES; INFORMATION PROCESSING; OPIATE ADDICTION; PSYCHOLOGY; SUBSTANCE-RELATED DISORDERS; DRUG DEPENDENCE; DRUG EFFECT; DRUG MISUSE; EVIDENCE BASED MEDICINE; HEALTH SURVEY; HOSPITAL ADMISSION; PRESCRIPTION; THERAPY EFFECT;

AMINES; BEHAVIOR, ADDICTIVE; CYCLOHEXANECARBOXYLIC ACIDS; DATA COLLECTION; DRUG SYNERGISM; GAMMA-AMINOBUTYRIC ACID; HUMANS; METHADONE; OPIOID-RELATED DISORDERS; SCOTLAND; SUBSTANCE-RELATED DISORDERS;

EID: 84886736559     PISSN: 10226877     EISSN: 14219891     Source Type: Journal    
DOI: 10.1159/000355268     Document Type: Article

References (24)

1. Dooley DJ, Taylor CP, Donevan S, Feltner D: Ca2+ channel a2delta; ligands: Novel modulators of neurotransmission. Trends Pharmacol Sci 2007; 28: 75-82.
2. Moore RA, Straube S, Wiffen PJ, Derry S, Mc-Quay HJ: Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009; 3: 007076.
3. Moore RA, Wiffen Philip J, Derry S, McQuay Henry J: Gabapentin for Chronic Neuropathic Pain and Fibromyalgia in Adults. Chichester, Wiley, 2011.
4. Peterson BL: Prevalence of gabapentin in impaired driving cases in Washington State in 2003-2007. J Anal Toxicol 2009; 33: 545-549.
5. National Institute for Health and Clinical Excellence Guidelines on the Management of Neuropathic Pain, 2010. Available from: Http://www.nice.org.uk/ nicemedia/live/12948/47936/47936.pdf (accessed July 2012).
6. Markowitz JS, Finkenbine R, Myrick H, King L, Carson WH: Gabapentin abuse in a cocaine user: Implications for treatment J Clin Psychopharmacol 1997; 17: 423-424.
7. Reccoppa L, Malcolm R, Ware M: Gabapentin abuse in inmates with prior history of cocaine dependence. Am J Addict 2004; 13: 321-323.
8. Victorri-Vigneau C, Guerlais M, Jolliet P: Abuse, dependency and withdrawal with gabapentin: A first case report. Pharmacopsychiatry 2007; 40: 43-44.
9. Bisaga A, Aharonovich E, Garawi F, Levin FR, Rubin E, Raby WN, et al: A randomized placebo-controlled trial of gabapentin for cocaine dependence. Drug Alcohol Depend 2006; 81: 267-274.
10. Gonzalez G, Desai R, Sofuoglu M, Poling J, Oliveto A, Gonsai K, et al: Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine-dependent methadone-treated patients. Drug Alcohol Depend 2007; 87: 1-9.
11. Chalabianloo F, Schjott J: Pregabalin and its potential for abuse (in Norwegian). Tidsskr Nor Laegeforen 2009; 129: 186-187.
12. Filipetto FA, Zipp CP, Coren JS: Potential for pregabalin abuse or diversion after past drugseeking behavior. J Am Osteopath Assoc 2010; 110: 605-607.
13. Grosshans M, Mutschler J, Hermann D, Klein O, Dressing H, Kiefer F, et al: Pregabalin abuse, dependence, and withdrawal: A case report. Am J Psychiatry 2010; 167: 869.
14. Westin AA, Strom EJ: Yes, pregabalin can be abused (in Norwegian). Tidsskr Nor Laegeforen 2010; 130: 2108.
15. Schifano F, D'Offizi S, Piccione M, Corazza O, Deluca P, Davey Z, et al: Is there a recreational misuse potential for pregabalin Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom 2011; 80: 118-122.
16. Schwan S, Sundstrom A, Stjernberg E, Hallberg E, Hallberg P: A signal for an abuse liability for pregabalin-results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol 2010; 66: 947-953.
17. Center for Drug Evaluation and Research, US Food and Drug Administration. Medical review(s): Lyrica (pregabalin) capsules. Pfizer, Inc., Appl. No. 21-446. Rockville/Md, Food and Drug Administration, 2004. Available from: Http://www.accessdata.fda.gov/drugsatfda-docs/nda/2004/021446-Lyrica% 20Capsules-medr.pdf (accessed July 2012).
18. Zacny JP, Paice JA, Coalson DW: Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers. Pharmacol Biochem Behav 2012; 100: 560-565.
19. Zhao J, Stockwell T, Macdonald S: Non-response bias in alcohol and drug population surveys. Drug Alcohol Rev 2009; 28: 648-657.
20. Fendrich M, Johnson TP, Wislar JS, Hubbell A, Spiehler V: The utility of drug testing in epidemiological research: Results from a general population survey. Addiction 2004; 99: 197-208.
21. Harrison L: The validity of self-reported drug use in survey research: An overview and critique of research methods. NIDA Res Monogr 1997; 167: 17-36.
22. General Register for Scotland Vital Events Reference Tables 2010 Section 6: Deaths-causes: 2010. Available from: Http://www.groscotland. gov.uk/statistics/theme/vitalevents/general/ref-tables/2010/deathscauses. html (accessed July 2012).
23. Rubio G, Bobes J, Cervera G, Ter?n A, P?rez M, L?pez-G?mez V, Rejas J: Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long-term benzodiazepine use. Eur Addict Res 2011; 17: 262-270.
24. Malcolm R, Myrick LH, Veatch LM, et al: Selfreported sleep, sleepiness and repeated alcohol withdrawals: A randomized, double-blind, controlled comparison of lorazepam vs. gabapentin. J Clin Sleep Med 2007; 3: 24-32.